Results 1 to 10 of about 77,084 (260)

G-quadruplex homeostasis is a determinant of PARP inhibitor toxicity in BRCA2-deficient cells [PDF]

Nature Communications
Inhibition of PARPs is a key strategy to treat tumours with defects in homologous recombination (HR), including those with mutations in the tumour suppressor gene BRCA2.
Abhishek Bharadwaj Sharma, Joanna Krwawicz, Leandre Tappenden, Muhammad Khairul Ramlee, Arwa A. Abugable, Xin Zhen, Simran Khurana, Travis H. Stracker, Nicholas D. Lakin   +8 more
doaj   +2 more sources

PARP inhibitor-based first-line maintenance therapy for newly diagnosed advanced ovarian cancer across molecular subgroups: an updated systematic review and network meta-analysis [PDF]

Frontiers in Oncology
BackgroundPARP inhibitor-based maintenance has become central to first-line treatment of newly diagnosed advanced ovarian cancer. With expanding therapeutic options, treatment selection increasingly relies on BRCA mutation and homologous recombination ...
Juntao Feng, Xiaomei Qin, Xiaoliang Mo
doaj   +2 more sources

ACSF2 Functions as a regulatory switch for PARP inhibitor sensitivity in platinum-sensitive and homologous recombination–proficient high-grade serous ovarian cancer [PDF]

Cancer Cell International
Background Poly(ADP-ribose) polymerase (PARP) inhibitor resistance represents a major clinical challenge in both homologous recombination deficiency-positive (HRD+) and deficiency-negative (HRD−) high-grade serous ovarian carcinoma (HGSOC).
Sijia Cheng, Jiayi Li, Yunzhi Ling, Jiaru Luo, Dan Zhou, Tianle Mao, Tingting Luo, Yanyang Tu, Jinlin Du, Minghui Zhou, Qingsong Qin, Yanqin Ji   +11 more
doaj   +2 more sources

Drug-Induced Interstitial Lung Disease From PARP Inhibitors (Olaparib and Niraparib) for Ovarian Cancer

Annals of Internal Medicine: Clinical Cases, 2023
Poly (ADP-ribose) polymerase (PARP) inhibitors are approved for the treatment of several types of cancers. We report a case of an 80-year-old Japanese woman who developed drug-induced interstitial lung disease (ILD) during treatment with PARP inhibitors (
Hiroshi Sugimoto, Takanori Enomoto, Mamoru Okuno, Naoko Chayahara, Hiroki Morita, Kyosuke Nakata   +5 more
doaj   +1 more source

Combined inhibition of PARP and EZH2 for cancer treatment: Current status, opportunities, and challenges

Frontiers in Pharmacology, 2022
Tumors with BRCA1/2 mutations or homologous recombination repair defects are sensitive to PARP inhibitors through the mechanism of synthetic lethality. Several PARP inhibitors are currently approved for ovarian, breast and pancreatic cancer in clinical ...
Xi Zhang, Xiao Huo, Xiao Huo, Hongyan Guo, Lixiang Xue, Lixiang Xue   +5 more
doaj   +1 more source

In silico screening identifies a novel small molecule inhibitor that counteracts PARP inhibitor resistance in ovarian cancer

Scientific Reports, 2021
Poly ADP-ribose polymerase (PARP) inhibitors are promising targeted therapy for epithelial ovarian cancer (EOC) with BRCA mutations or defective homologous recombination (HR) repair. However, reversion of BRCA mutation and restoration of HR repair in EOC
Z. Ping Lin, Nour N. Al Zouabi, Mark L. Xu, Nicole E. Bowen, Terence L. Wu, Ethan S. Lavi, Pamela H. Huang, Yong-Lian Zhu, Baek Kim, Elena S. Ratner   +9 more
doaj   +1 more source

PARP inhibition promotes ferroptosis via repressing SLC7A11 and synergizes with ferroptosis inducers in BRCA-proficient ovarian cancer

Redox Biology, 2021
Pharmacologic inhibition of PARP is the primary therapeutic strategy for BRCA mutant ovarian cancer. However, most of patients carry wild-type BRCA1/2 with no significant clinical benefits from PARP inhibitors, calling for the needs to further ...
Ting Hong, Guang Lei, Xue Chen, He Li, Xiaoye Zhang, Nayiyuan Wu, Yu Zhao, Yilei Zhang, Jing Wang   +8 more
doaj   +1 more source

A ribosomal gene panel predicting a novel synthetic lethality in non-BRCAness tumors

Signal Transduction and Targeted Therapy, 2023
Poly (ADP-ribose) polymerase (PARP) inhibitors are one of the most exciting classes of targeted therapy agents for cancers with homologous recombination (HR) deficiency.
Chao Zhang, Qiang Guo, Lifeng Chen, Zheming Wu, Xiao-Jian Yan, Chengyang Zou, Qiuxue Zhang, Jiahong Tan, Tian Fang, Qunxian Rao, Yang Li, Shizhen Shen, Min Deng, Liewei Wang, Huanyao Gao, Jia Yu, Hu Li, Cheng Zhang, Somaira Nowsheen, Jake Kloeber, Fei Zhao, Ping Yin, Chunbo Teng, Zhongqiu Lin, Kun Song, Shuzhong Yao, Liangqing Yao, Lingying Wu, Yong Zhang, Xiaodong Cheng, Qinglei Gao, Jian Yuan, Zhenkun Lou, Jin-San Zhang   +33 more
doaj   +1 more source

99529 The Role of ATF6-Mediated Signaling in PARP Inhibitor Resistant Ovarian Cancer

Journal of Clinical and Translational Science, 2021
IMPACT: This work has the potential to identify targetable pathways conveying resistance to PARP inhibitors that may improve ovarian cancer patient outcomes. OBJECTIVES/GOALS: High grade serous ovarian cancer is the deadliest gynecologic malignancy. PARP
Alexandra, Benjamin Bitler
doaj   +1 more source

PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer

npj Precision Oncology, 2022
PARP inhibitors were recently approved for treatment of molecularly-defined subsets of metastatic castrate-resistant prostate cancer (mCRPC) patients.
Kasia M. Dillon, Raie T. Bekele, Zsofia Sztupinszki, Timothy Hanlon, Shahrzad Rafiei, Zoltan Szallasi, Atish D. Choudhury, Kent W. Mouw   +7 more
doaj   +1 more source